12 March 2015
WHO publishes first guidelines for hepatitis B treatment
- European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
Citation style for this article: Eurosurveillance editorial team. WHO publishes first guidelines for hepatitis B treatment. Euro Surveill. 2015;20(10):pii=21061. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21061
Date of submission:
The World Health Organization (WHO) issued today its first hepatitis B treatment guidelines: ‘Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection’, laying out a simplified approach to the care and treatment of persons living with chronic hepatitis B infection .
These guidelines are intended for country programme managers to help plan the development and scale up of hepatitis B prevention, care and treatment and also for healthcare providers who care for persons infected with hepatitis B virus (HBV).
Key recommendations include:
- the use of simple non-invasive tests to assess the stage of liver disease;
- prioritising treatment for those with most advanced stage of liver disease;
- the use of safe and effective medicines for treatment;
- regular monitoring using simple tests for early detection of liver cancer, to assess whether treatment is working, and if treatment can be stopped.
The special needs of specific populations, such as people co-infected with HIV, children and adolescents, and pregnant women are also considered.
Existing recommendations for the prevention of HBV transmission from relevant WHO guidelines are also summarised in the newly published guidelines and include prevention of perinatal and early childhood HBV infection through infant hepatitis B vaccination; catch-up vaccination and other prevention strategies in key affected populations (people who inject drugs, men who have sex with men, sex workers) as well as prevention of transmission in healthcare settings.
Hepatitis B infection is caused by the HBV, an enveloped DNA virus that infects the liver, causing hepatocellular necrosis and inflammation. Chronic hepatitis B – defined as persistence of hepatitis B surface antigen (HBsAg) for six months or more – is a major public health problem.
- World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO. Mar 2015. Available from: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1
The opinions expressed by authors contributing to Eurosurveillance
do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance
site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence
. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Eurosurveillance [ISSN] - ©2007-2016. All rights reserved